Table GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) [see all tables in this series...]

Part (iii) Lifetime prevalence young adults: last survey available for each Member State (from 2000 onwards)

Country		Geographical area	Year	Reference	Age range young adults	Sample size young adults	Cannabis (%)	Cocaine (%) (1)	Amphetamines (%) (2)	Ecstasy (%) (3)	LSD (%)
Belgium		National	2004	(6)	15–34	:	23.7	:	:	:	:
Bulgaria		National	2008	(3)	15–34	2164	14.3	3.0	4.4	3.6	0.4
Czech Republic		National	2008	(3)	15–34	2079	53.3	3.6	7.8	18.4	10.3
Denmark		National	2008	(5)	16–34	1744	48.0	9.5	10.5	4.5	1.6
Germany		National	2006	(7)	18–34	3306	37.5	4.9	5.1	5.6	2.9
Estonia		National	2008	(3)	15–34	545	:	:	:	:	:
Ireland		National	2006–07	(5)	15–34	:	28.6	8.2	5.1	9.0	3.6
Greece		National (except Aegean and Ionian Islands)	2004	(3)	15–34	2620	10.8	1.0	0.2	0.6	0.4
Spain		National	2007-08	(7)	15–34	9843	37.3	11.8	5.5	7.1	:
France		National	2005	(6)	15–34	10855	43.6	3.5	1.3	3.7	1.6
Italy		National	2008	(4)	15–34	6398	37.5	7.6	3.4	3.8	:
Cyprus		National	2006	(1)	15–34	1753	9.9	1.4	0.8	2.4	1.0
Latvia		National	2007	(2)	15–34	2497	21.7	4.0	6.1	8.5	2.3
Lithuania		National	2008	(2)	15–34	2152	21.2	0.7	2.5	3.9	0.7
Luxembourg		:	:	:	:	:	:	:	:	:	:
Hungary		National	2007	(3)	18-34	1111	19.1	1.8	4.0	5.1	2.4
Malta		National	2001	(1)	18–34	640	4.8	0.9	0.7	1.4	0.5
Netherlands		National	2005	(3)	15–34	:	32.3	4.9	3.0	8.1	1.5
Austria		National	2008	(2)	15–34	2558	19.2	2.8	3.1	3.3	1.9
Poland		National	2006	(2)	15–34	2031	16.1	1.3	4.8	2.1	1.6
Portugal		National	2007	(2)	15–34	4765	17.0	2.8	1.3	2.6	0.9
Romania		National	2007	(2)	15–34	2262	2.9	0.1	0.1	0.6	0.0
Slovenia		National	2007	(1)	15–34	691	:	:	:	:	:
Slovakia		National	2006	(6)	15–34	556	28.6	2.0	2.4	8.4	:
Finland		National	2006	(7)	15–34	1387	22.1	1.7	4.7	3.6	1.2
Sweden		National	2008	(5)	15–34	16271	19.2	4.6	5.7	3.7	:
Sweden		National	2008	(10)	16-34	2546	16.2	:	:	:	:
United Kingdom		England and Wales	2008-09	(12)	16-34	9683	40.5	14.9	15.4	13.8	6.1
United Kingdom		Northern Ireland	2007-08	(16)	16-34	919	28.8	7.7	10.5	13.2	6.1
United Kingdom		Scotland	2006	(19)	16–34	1115	49.6	15.5	22.1	19.4	11.6
United Kingdom		United Kingdom	2006	(21)	16–34	:	41.9	12.8	16.8	13.5	7.5
Croatia		:	:	:	:	:	:	:	:	:	:
Turkey		:	:	:	:	:	:	:	:	:	:
Norway		National	2004	(2)	15–34	1238	25.5	4.3	5.9	3.6	1.7

Notes:

 (1) Cocaine, any form. 

 (2) For Belgium National 2001 and for Metropolitan France 1995: amphetamine and ecstasy. 

 (3) For Spain: ecstasy and other designer drugs. 

 This table aims to provide an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as a reference point for the 1993 survey. 

 In surveys with small sample sizes results should be interpreted with caution. 

 Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15–64, young adults: 15–34). In countries where age ranges are more restrictive, prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups. 

 Data on hallucinogenic mushrooms is not provided in the Statistical Bulletin due to the fact that few countries report comparable information. In the few countries providing data lifetime prevalence estimates for young adults range from 0.3% to 14.4%, and last year prevalence estimates between 0.2% and 5.8%. 

 For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions. 

 See also 'General notes for interpreting data' on the Explanatory notes and help page. 

Sources:

 See Table GPS-0.  

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)